Save Article

Regeneron, P&G Expand Pact
To Include Obesity Treatments

Dow Jones Newswires

Updated Sept. 30, 1997 3:56 p.m. ET

TARRYTOWN, N.Y. -- Regeneron Pharmaceuticals Inc. and Procter & Gamble said Tuesday they expanded their 10-year research agreement to include development of nerve-regenerating drug products aimed at treating obesity associated with Type II, or late-onset, diabetes.

In early afternoon trading on the Nasdaq Stock Market, Regeneron's shares were up $1.5625, or 16%, to $11.375. Procter & Gamble, which has a 17% stake in Regeneron,...